A Study of Human Rhinovirus Type 16 (HRV-16) Following Administration in the Nose of Healthy Adult Volunteers

Inclusion Criteria: * Demonstrate an understanding of the study and sign an informed consent form prior to any study-related procedures * Healthy with no clinically significant abnormalities as determined by medical history * Women must be neither pregnant nor lactating (producing breast milk) and have a negative urine pregnancy test at Screening Visit 1 * Women of child-bearing potential and all men must agree to use adequate birth control measures (as determined by the investigator) and must agree to continue to use such measures and not plan a pregnancy until after the Day 6 visit * Men must agree not to donate sperm during the study through the Day 6 visit Exclusion Criteria: * Have a documented serum-neutralizing antibody titer of \> 2-fold dilution to HRV-16 in the blood sample within approximately 40 days of Screening Visit 2 * Live with a family member who cares for the elderly, infants, or small children (eg, nursing home or day care provider), or live with someone who has a chronic lung disease, premature infant, or immunocompromised individual * Require a prescription or over-the-counter medication on a regular basis (3 or more times per week), except contraceptive preparations, hormone replacement therapy, or topical acne medication * Have a history of chronic disease that the Investigator believes are clinically significant * Have a history of chronic headaches (eg frequent migraines, cluster headaches) with 3 or more headaches per week